This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Buy 3 MedTech Stocks That Are Outperforming S&P 500 in 2021
by Sriparna Ghosal
Let's take a look at the three MedTech stocks performing well lately, banking on a host of impressive developments.
Zacks.com featured highlights include: Rocky Brands, Stamps.com, Owens & Minor, Natus Medical and Toyota Motor
by Zacks Equity Research
Zacks.com featured highlights include: Rocky Brands, Stamps.com, Owens & Minor, Natus Medical and Toyota Motor
Combat the Choppy Market With These 5 Low-Beta Stocks
by Nilanjan Banerjee
It is imperative to build a portfolio of low-beta stocks to sail through the choppy market. RCKY, STMP, OMI, NTUS & TM are the frontrunners.
Top Ranked Growth Stocks to Buy for March 31st
by Zacks Equity Research
TPX, HIBB, and OMI made it to the Zacks Rank #1 (Strong Buy) growth stocks list on March 31, 2021
Syneos Health (SYNH) New Partnership to Enhance Clinical Trials
by Zacks Equity Research
Syneos Health (SYNH) new partnership will extend the company's mission to boost research and enable universal patient and provider access with clinical research services.
Top Ranked Growth Stocks to Buy for March 29th
by Zacks Equity Research
HIBB, TPX and OMI made it to the Zacks Rank #1 (Strong Buy) growth stocks list on March 29, 2021
Owens & Minor, eHealth, Portland General Electric Co, Avangrid and Avista Corp highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Owens & Minor, eHealth, Portland General Electric Co, Avangrid and Avista Corp highlighted as Zacks Bull and Bear of the Day
Bull of the Day: Owens and Minor (OMI)
by David Borun
This medical logistics company made big gains in 2020 - and is poised to keep heading higher.
Top Ranked Growth Stocks to Buy for March 25th
by Zacks Equity Research
TPX, OMI, WLK, and REPYY made it to the Zacks Rank #1 (Strong Buy) growth stocks list on March 25, 2021
Why Owens & Minor (OMI) Could Be an Impressive Growth Stock
by Zacks Equity Research
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Owens & Minor (OMI).
Here's Why You Should Add Haemonetics (HAE) to Your Portfolio
by Zacks Equity Research
Investor are optimistic about Haemonetics (HAE) on its continued Plasma franchise growth and huge potential of Hemostasis Management franchise.
Abbott (ABT) Nutrition Shows Robust Momentum Amid Pandemic
by Zacks Equity Research
Within Medical Device, Abbott (ABT) Diabetes Care business has been in the limelight for developments in its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.
Top 6 Relative Price Strength Stocks That You Need to Buy
by Nilanjan Choudhury
USA Truck (USAK), Olin Corporation (OLN), Williams-Sonoma (WSM), Owens & Minor (OMI), Virtu Financial (VIRT) and TTEC Holdings (TTEC) are six stocks with explosive relative price strength.
Cardiovascular Systems' (CSII) New Buyout Boosts CAD/PAD Line
by Zacks Equity Research
Cardiovascular Systems' (CSII) acquisition of Peripheral Support Catheters will enhance outcomes for patients undergoing complex peripheral and coronary interventions.
Owens & Minor (OMI) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Owens & Minor (OMI) closed at $37.75, marking a -1.87% move from the previous day.
Top Ranked Growth Stocks to Buy for March 22nd
by Zacks Equity Research
UEIC, HRI, OMI, and REPYY made it to the Zacks Rank #1 (Strong Buy) growth stocks list on March 22, 2021
Insulet's (PODD) Omnipod 5 Pivotal Trial Outcome Favorable
by Zacks Equity Research
Insulet's (PODD) Omnipod 5 pivotal study showed improvement in glucose control, verified by notable reduction in HbA1c and enhanced time in range together with the lowest rates of hypoglycemia.
NuVasive (NUVA) Hits a New 52-Week High: What's Driving It?
by Zacks Equity Research
NuVasive (NUVA) is optimistic about its strong international performance and a huge growth potential in the spine market.
Penumbra (PEN) Launches INDIGO System Lightning 7 in US
by Zacks Equity Research
Penumbra's (PEN) INDIGO System Lightning 7 assists physicians in easing arterial thrombus removal with single-session results.
Zacks.com featured highlights include: Vishay Intertechnology, PVH Corp, Owens & Minor and Sanmina Corp
by Zacks Equity Research
Zacks.com featured highlights include: Vishay Intertechnology, PVH Corp, Owens & Minor and Sanmina Corp
Buy These 7 Stocks With Low P/B Ratio to Boost Returns
by Kinjel Shah
P/B ratio is emerging as a convenient tool for identifying low-priced stocks that have high growth prospects. PVH Corp. (PVH), Honda Motor (HMC), Owens & Minor (OMI), ArcelorMittal (MT), Hologic (HOLX), ASE Technology Holding (ASX) and Goldman Sachs (GS) are good stocks to add.
Cardiovascular Systems' (CSII) WIRION Cures 1st U.S Patient
by Zacks Equity Research
Cardiovascular Systems' (CSII) WIRION demonstrated a major adverse event rate of 1.9%, which is lower than the earlier reported rates for other lower extremity embolic protection filters.
Create a Standout Portfolio With These 4 Low P/CF Stocks
by Sumit Singh
Value investing is essentially about selecting stocks that are usually cheap but fundamentally sound. Vishay Intertechnology (VSH), PVH Corp. (PVH), Owens & Minor (OMI) and Sanmina Corporation (SANM) boast low P/CF ratio.
Top Ranked Growth Stocks to Buy for March 17th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, March 17th
Owens & Minor (OMI) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Owens & Minor (OMI) closed at $35.98, marking a -1.72% move from the previous day.